Our Story

Sol-Gel is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. Our lead product candidates, VERED for the treatment of papulopustular rosacea and TWIN and SIRS-T for the treatment of acne vulgaris (“acne”) are based upon our proprietary microencapsulation delivery system. This technology consists of microcapsules made of silica.  Based on our pre-clinical and clinical data, this delivery system should enable us to develop and commercialize dermatological drug products that are more effective and/or have fewer side effects than currently marketed drugs.
Our silica-based delivery system improves the tolerability of topical dermatological drug products by entrapping drug substances in porous silica microcapsules. This creates a protective barrier between the drug substance and the skin and controls the release rate of the drug substance. Our delivery system also enables to produce novel fixed-dose combinations that otherwise would not be stable, by encasing unstable drug substances within a protective silica shell.
Our lead product candidates also include E-06, a fixed-dose combination of an antifungal drug substance and a mid-potency steroid for the treatment of symptomatic interdigital tinea pedis (inflamed athlete's foot). E-06 is expected to rapidly relieve inflammatory signs and symptoms such as erythema, itching, burning and maceration, thereby improving patient comfort and compliance.
In addition to novel product candidates, our pipeline also a generic drug product, which we aim to be the first-to-file.
In order to protect Sol-Gel's intellectual property, we have established a patent portfolio that includes 6 granted patents and over 12 pending patent applications describing and claiming our proprietary processes, formulations and methods of use for our silica microencapsulation platform and other technologies in North America, and in addition to 5 granted patents and 13 pending patent applications in certain other countries worldwide.
In 2014, we were acquired by Mr. Moshe (Mori) Arkin, who serves as the Chairman of our Board of Directors. Mr. Arkin has extensive experience in the development and commercialization of dermatology drug products, having held leadership roles in several dermatology companies and having extensive ties to leading innovative and generic drug companies. Among other positions, Mr. Arkin headed Agis, expanding it into becoming a leading dermatological company in the U.S. until its acquisition by Perrigo in March 2005 for $818 million.
We are proud that Sol-Gel was co-founded by Professor David Avnir of The Hebrew University. Professor Avnir pioneered the field of organic-doped sol-gel ceramics and was the first Chairman of the Board of the International Sol-Gel Society (ISGS). His innovative work continues to inspire the company to this day.